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Abstract 
AT THE OUTSET, the Athlome Project aims to collectively study the genotype and phenotype 
data currently available on elite athletes, in adaptation to exercise training (in both human and 
animal models) and on exercise-related musculoskeletal injuries from individual studies and 
from consortia worldwide. To achieve this, several steps are set out: 
1) To establish an ethically sound international research consortium (Athlome Project 
Consortium) and biobank resource systematically across individual centers; 
2) To discover genetic variants associated with exercise performance, adaptive response to 
exercise-training, and skeletal-muscle injuries using the genome-wide association study 
(GWAS) approach, targeted sequencing or whole genome sequencing, where possible; 
3) To validate and replicate the genetic markers from the discovery phase across sex and 
ethnicity; and 
4) To conduct functional investigations following replicated findings [e.g., study the 
replicated single nucleotide polymorphisms (SNPs) and their linkage disequilibrium regions, 
in vitro expression studies and knockouts of nearby genes] to better understand the associated 
biology. 
During the development of the initial phase of the Athlome Project, in determining the 
genetic variations related to elite athletic performance and injury predisposition, epigenomic, 
transcriptomic, and proteomic analyses need also be carefully planned to strengthen the 
understanding of gene functions. Linking these findings with metabolic profiling (the end 
products of the cellular processes) is also a future aspiration of the Athlome Project. Another 
challenge is to be able to efficiently integrate the multiple “omics” datasets generated from 
the different approaches. The ultimate goal of the Athlome Project Consortium is to generate 
the ethically sound environment, interest, and capacity needed to develop the specialist 
knowledge to inform personalized training and injury prevention, as well as doping detection. 
The following individual or collaborative study groups have agreed to work together in the 
global partnership that constitutes the Athlome Project Consortium. The participating cohorts 
and the focus of each are depicted in Fig. 1. 
Eastern Europe Population Studies (The Russian and Belarusian Cohorts, 
GELAK, GELAV, and GUAP) 
The Russian and Belarusian cohorts, the Genetics and Epigenetics of Lithuanian Athletes 
from Kaunas (GELAK) and Vilnius (GELAV), and the Genome of Ukrainian Athletes 
Project (GUAP) have consolidated to identify genetic and epigenetic variations associated 
with high-level sports performance. The cohort comprises East Europeans (from Belarus, 
Lithuania, Russia, and Ukraine; in total n = 8,228 athletes and n = 4,121 controls). The 
athletes are grouped into international (including participants in Olympics and world 
championships), national, regional, or local/noncompetitive categories. These include 
biathletes, distance runners, cyclists, triathletes, kayakers, rowers, canoers, modern 
pentathletes, orienteers, skiers, speed skaters, short-trackers, walkers, weightlifters, 
bodybuilders, powerlifters, strongmen, sprint runners (≤ 400 m), sprint swimmers (50–100 
m), decathletes, heptathletes, combat athletes, field athletes, bobsleigh athletes, rhythmic and 
artistic gymnasts, figure skaters, fencers, and team ball-sport players. A portion of the 
participants have been evaluated with a variety of quantitative performance- and health-
related assessments, including strength/power-related measurements, agility/speed-related 
measurements, balance, flexibility and coordination measurements, endurance-related 
measurement, skeletal muscle biopsy, and health-related measurements. 
Principal Investigators: Ildus I. Ahmetov [Volga Region State Academy of Physical Culture, 
Sport and Tourism, Russia (RUS)], Svitlana B. Drozdovska [National University of Physical 
Education of Ukraine, Ukraine (UKR)], Colin N. Moran [University of Stirling, United 
Kingdom (UK)], Valentina Ginevičienė [Vilnius University, Lithuania (LTU)], Andrei A. 
Gilep [Institute of Bioorganic Chemistry NASB, Belaurs (BLR)]. 
ELITE http://elite.stanford.edu 
The Exercise at the Limit - Inherited Traits of Endurance (ELITE) consortium is a global 
initiative with the main objective to map the role that genetics plays in athletic ability vs. 
environmental factors, such as training. Study participant (n > 600) selection is based on a 
physiological variable relevant for both health and sport performance, i.e., maximum oxygen 
uptake (V̇O2max). The main inclusion criterion is V̇O2max > 75 ml·kg−1·min−1 for men and > 63 
ml·kg−1·min−1 for women, respectively. The consortium is continuously expanding and is 
recruiting athletes from all over the globe (with main focus on Caucasians, North East 
Africans, East Asians, and South Americans) who are successful in endurance sports 
(running, cycling, cross-country skiing, triathlon, and rowing). Analyses currently include 
enhanced whole exome sequencing and GWAS (1.7 million SNPs). The combination of 
analytic methods will enable findings and differentiation between common variants with 
small effects and novel rare variants with larger effects. The aim is also to investigate sex and 
ethnic differences. 
Principal Investigators: Euan A. Ashley, C. Mikael Mattsson, Matthew Wheeler, Daryl 
Waggott (Stanford University, USA). 
Elite East African Athlete Cohort 
The consortium also aims to study the East African running success by analyzing data from 
previously recruited subjects: 1) 76 endurance runners (64 men) and 38 sprint and power 
event athletes (18 men) from the Ethiopian national athletics teams, 315 controls from the 
general Ethiopian population (281 men), 93 controls from the Arsi region of Ethiopia (80 
men) and 2) 291 elite Kenyan endurance athletes (232 men) and 85 control participants (40 
men). Seventy (59 men) Kenyan athletes had competed internationally and achieved 
outstanding success. 
Principal Investigators: Yannis Pitsiladis (University of Brighton, UK), Robert Scott 
(University of Cambridge, UK). 
GAMES 
An international consortium (GAMES) was established to compare allele frequencies 
between elite endurance athletes and ethnicity-matched controls. GWASs were undertaken on 
two cohorts of elite endurance athletes (GENATHLETE and Japanese endurance runners) and 
their respective controls, from which a panel of 45 candidate SNPs was identified. These 
markers were tested for replication in seven additional cohorts of endurance athletes and 
controls from Australia, Ethiopia, Japan, Kenya, Poland, Russia, and Spain. The study is 
based on a total of 1,520 endurance athletes (835 of them had competed in world 
championships or Olympic Games) and 2,760 controls. 
Principal Investigators: Claude Bouchard, Tuomo Rankinen (Pennington Biomedical 
Research Center, Louisiana State University, USA), Noriyuki Fuku [Juntendo University, 
Japan (JPN)], Yannis Pitsiladis (University of Brighton, UK), Bernd Wolfarth [Humboldt 
University, Germany (DEU)], Alejandro Lucia [Universidad Europea de Madrid, Spain 
(ESP)]. 
GENATHLETE 
The study was launched in 1993 with the aim of identifying DNA variants that are present at 
different frequencies between elite endurance athletes and sedentary controls. Male endurance 
athletes and controls were recruited from Canada, Finland, Germany, and the USA. The 
cohort assembled to date includes 315 elite endurance athletes and 320 matched controls. 
Selection criteria for the all-male endurance athlete sample include that they had to be athletes 
of national or international caliber with a V̇O2max of at least 75 ml·kg−1·min−1. The mean value 
for the 315 athletes is currently 79 ml·kg−1·min−1, while the mean for the 320 control subjects 
reached 40 ml·kg−1·min−1. Multiple candidate genes have been studied using the resources of 
GENATHLETE. A genome-wide screen for common variants has been performed on 
GENATHLETE (see GAMES cohort above) and further studies are focusing on nuclear and 
mitochondrial DNA sequencing. 
Principal Investigators: Claude Bouchard, Tuomo Rankinen (Pennington Biomedical 
Research Center, Louisiana State University System, USA), Bernd Wolfarth (Department of 
Sports Medicine, Charité Medical School, Berlin, DEU), Louis Perusse (Laval University, 
Quebec, Canada), Rainer Rauramaa (University of Eastern Finland, Kuopio, Finland). 
GENESIS 
The GENetics of Elite Status In Sport (GENESIS) consortium aims to identify molecular 
genetic characteristics associated with successful sports performance. The cohort (current n > 
1,200) is mainly composed of UK athletes. Sports include marathon running and other track-
and-field athletics, cycling, and team sports (e.g., soccer). The RugbyGene Study is a major 
subcomponent of GENESIS and focuses on rugby (both union and league codes). Objectives 
of GENESIS are: 1) to increase current cohort size substantially, 2) to apply hypothesis-free 
approaches to identify molecular genomic markers, 3) to expand GENESIS from genomics to 
other omics, and 4) to combine the omics data with athlete health and performance data to 
maximize practical impact of GENESIS. 
Principal Investigators: Alun G. Williams, Stephen H. Day, Georgina K. Stebbings 
(Manchester Metropolitan University, UK), Robert M. Erskine (Liverpool John Moores 
University, UK), Hugh E. Montgomery (University College London, UK). 
Gene SMART Study http://www.vu.edu.au/speed-gene 
The Gene SMART (Skeletal Muscle Adaptive Response to Training) study aims to identify 
the gene variants that predict the skeletal muscle response to both a single bout and 4 wk of 
high-intensity interval training in three different training centers. While the lead training and 
testing center is located in Victoria University, Melbourne, two other centers have been 
launched at Bond University, Australia, and the University of Sao Paulo, Brazil. A fourth 
center (University of Brighton, UK) will focus on the omics analyses. The cohort comprises 
moderately trained, healthy male participants (aged 20–45 yr, body mass index ≤30 kg/m2). 
Participants are undergoing similar exercise testing and exercise training in three different 
laboratories. Dietary habits are assessed by questionnaire and nutritionist consultation. 
Activity history is assessed by questionnaire and current activity level is assessed by activity 
monitoring. A number of muscle and blood analyses are to be performed, including 
genotyping, mitochondrial respiration, transcriptomics, proteomics, and enzyme activity 
before, during and after training, where appropriate. Currently ∼40 participants have finished 
the study, and the aim is to train a total of 250 participants. The Gene SMART also includes 
baseline and posttraining testing and sampling for all participants. 
Principal Investigators: David Bishop, Nir Eynon [Victoria University, Australia (AUS)]. 
GOINg 
The recently established Genomics Of INjuries (GOINg) consortium aims to identify DNA 
variants that modify the risk of anterior cruciate ligament (ACL) injuries. It is the only 
consortium within the Athlome Project to specifically investigate exercise-associated 
musculoskeletal injuries. The plan is to screen current known loci for ACL injury 
susceptibility in larger data sets in an attempt to determine if they remain as susceptibility loci 
across all populations using the hypothesis-driven candidate gene case-control study design. 
Care will be taken to use the same criteria to accurately phenotype, with respect to ancestry, 
sporting, and occupational details, injury profile and mechanism(s) of injury, other injury 
history and family history, as well as other appropriate medical history and medication use. 
The actual functional significance of the identified variants will also be investigated. This 
initial phase will be followed by sequencing and the research objectives will be eventually 
expanded to include other omics. Thus far, ACL rupture consortium has collected DNA 
samples and clinical, as well as physical and occupational activity information from subjects 
from South Africa, Poland, Australia, Russia, and Italy. 
Principal Investigators: Malcolm Collins, Alison September, Michael Posthumus [University 
of Cape Town, South Africa (ZAF)], Nir Eynon (Victoria University, AUS), Pawel Cieszczyk 
[University of Szczecin, Poland (POL)]. 
J-HAP 
The Japanese Human Athlome Project (J-HAP) focuses on the study of genes associated with 
physical performance and its related phenotypes (e.g., muscle mass, muscle fiber type, 
V̇O2max). The cohort comprises Japanese athletes (currently > 2,400, mainly international and 
national levels) and healthy Japanese controls (currently > 1,000). These athletes are mainly 
track-and-field athletes and swimmers competing in endurance- and sprint/power-oriented 
events. Multiple omics approaches will be used to determine genes in talent identification in 
the Japanese population. Among the collected Japanese athletes' and controls' samples, ∼200 
muscle biopsies were obtained from both athletes and controls to investigate genetic variants 
associated with muscle fiber type distribution. 
Primary Investigators: Noriyuki Fuku (Juntendo University, JPN), Naoki Kikuchi (Nippon 
Sport Science University, JPN), Eri Miyamoto-Mikami (The National Institute of Fitness and 
Sports in Kanoya, JPN). 
NTR 
The Netherlands Twin Register (NTR) is a population-based cohort recruiting both newborn 
and adult multiples and their family members with continuous longitudinal data collection. In 
the past 25+ yr, around 40% of all twins and multiples in the Netherlands have taken part in 
the NTR research projects. Family members and spouses of twins also took part, leading to a 
total of over 185,000 participants across multiple research projects. The longitudinal 
information that has been collected extends from genotype to biomarkers, gene expression to 
rich behavioral information including biennial reports on (competitive) sports participation 
and performance level and on injuries related to sports. In its sports research track, NTR aims 
to understand the interplay between genetic and environmental factors shaping individual 
differences in sports participation and performance. In the NTR, participants are recruited as 
newborns and followed into young adulthood, 520 have played competitively at a regional 
and 189 at a national level. The main sports that Dutch adolescents/young adults engage in 
are swimming, tennis, bicycling, soccer, and field hockey. The longitudinal data collection of 
the NTR is ongoing and securely funded for the next 5 yr. 
Principal Investigators: Eco de Geus, Meike Bartels [Vrije Universiteit (VU University) and 
VU Medical Centre, the Netherlands (NLD)]. 
POWERGENE 
The POWERGENE consortium aims to characterize the elite sprint/power athlete genotype. 
The internationally competitive (Olympic/world championship qualifiers) sprint/power 
athletes are from: Australia, Belgium, Greece, Italy, Jamaica, Japan, Lithuania, Poland, Spain, 
the USA, Brazil, and Russia. They will be compared with subelite athletes (national 
qualifiers), endurance athletes, team athletes, and controls. The current cohort consists of 
female (n = 264) and male (n = 481) specialist power athletes across three major ethnicities 
(i.e., European, West African, and East Asian ancestries). Sprint/power athletes include those 
individuals competing in track (≤ 800 m) and field (jump, throw) events, cycling (track), 
swimming (≤ 200 m), gymnastics (artistic), weightlifting, judo, speed-skating, and power 
lifting. Endurance athletes (n = 586) include track and road running specialists (> 800 m), 
rowers, cyclists, swimmers (> 200 m), triathletes and ironmen. Team sports (n = 862) include 
football (soccer), cricket, hockey, volleyball, and basketball. 
Principal Investigators: Yannis Pitsiladis (University of Brighton, UK), Kathryn North 
(Murdoch Childrens Research Institute, AUS), Nir Eynon (Victoria University, AUS). 
Super-athletes: Genes and Sweat 
The study aims to 1) identify genetic variants associated with elite athletic performance, 2) 
study potential ethnic differences, and 3) study the functional significance of the identified 
variants. A GWAS will be carried out in 3,000 consented elite athletes, tested negative for 
doping substances at the Anti-Doping Laboratories, Federazione Medico Sportiva Italiana 
(FMSI), and Anti-Doping Lab Qatar (ADLQ), using Illumina genotyping technologies. 
Examining genotype frequency distribution of elite athletes from European countries (where 
most of FMSI samples will be obtained) against those from South Asian and African 
countries (where most of ADLQ samples are expected to be obtained) would help to identify 
potential ethnic differences in the genetic predisposition to athletic performance. 
Subsequently, urine metabolome in a subset of these athletes (1,000 subjects) will be 
performed and will be related to the athlete's sporting discipline. 
Principal Investigators: Mohamed El-Rayess, Costas Georgakopoulos, Mohammed Alsayrafi 
[ADLQ, Qatar (QAT)], Francesco Botre [FMSI, Italy (ITA)], Karsten Suhre (Weill Cornell 
Medical College in Qatar, QAT), Mike Hubank (University College London, UK). 
Epigenetics of Elite Athletic Performance 
It is clear from animal and human studies that epigenetic marks play a role in the modulation 
of gene expression in relevant tissues. There also are indications that epigenetic marks can be 
altered by acute and chronic exercise in skeletal muscle and adipose tissue where they have 
been studied. Thus individual differences in any exercise-related traits can potentially be 
explained not only by the impact of DNA sequence variation on biology and behavior but 
also by the effects of epigenomic signaling on gene expression. We are formulating the 
hypothesis that elite athletic performance is influenced by epigenomic alterations, facilitating 
morphological, physiological, metabolic, cognitive, emotional, and behavioral changes that 
empower the athlete to push performance beyond existing boundaries. We envisage testing 
this hypothesis by recruiting twin athletes competing at the Olympic or world championship 
levels. 
Principal Investigators: Vassilis Klissouras [University of Athens, Greece (GRC)], Yannis 
Pitsiladis (University of Brighton, UK). 
Rat Models of Exercise and Health (LCR-HCR rat model) 
The purpose of the Low Capacity Rats-High Capacity Rats (LCR-HCR) model is to serve as a 
resource for the in-depth study of rat models to resolve the extremes of exercise and health. 
By connecting clinical observation with a theoretical base, the working hypothesis is that: 
variation in capacity for energy transfer is the central mechanistic determinant between 
disease and health (energy transfer hypothesis). As an unbiased test of this hypothesis, this 
study showed that two-way artificial selective breeding of rats for low and high intrinsic 
endurance exercise capacity also produced rats that differed for numerous disease risks, 
including the metabolic syndrome, premature aging, fatty liver disease, obesity, and 
Alzheimer's disease. Exercise capacity is a result of intrinsic capacity plus adaptation to all 
aspects of physical activity. To capture this biology, rats for low and high response to 8 wk of 
treadmill running exercise were selectively bred. Thus, the study has models that represent 
the four “corners” of exercise capacity. These contrasting animal model systems may prove to 
be translationally superior relative to more widely used simplistic models for understanding 
disease conditions. The rat models may be deeply explored to discover causal mechanisms 
and develop effective therapeutics. These rats are being studied at over 50 institutions in 11 
countries. 
Principal Investigators: Steven Britton, Lauren Koch (University of Michigan, USA). 
1000 Athlomes Project 
The 1000 Athlomes Project aims to sequence 1000 genomes of sprinters and distance runners 
of West and East African descent. Phase 1 of the project has already commended and 
involves the sequencing of 12 sprinters and 12 distance runners of the highest level (i.e., 
world record holders, Olympians, and world champions). Phase 2 (2016–2018) will involve 
increasing the sample size for sequencing to 100 genomes. The pool of the runners to be 
sequenced will be expanded to 1,000 by 2020 (phase 3). An important aim of this sequencing 
project is to document the genotype distribution of elite East and West African athletes. The 
large amount of genotype data to be generated from the 1000 Athlomes Project will serve 
as 1) a reference panel for future performance studies and 2) a guide for other extreme 
phenotype studies in medical science. 
Principal Investigators: Masashi Tanaka (Tokyo Metropolitan Institute of Gerontology, JPN), 
Yannis Pitsiladis (University of Brighton, UK). 
Ethical Principles for Athlome Biobanking 
The rise of biobanking has brought about a whole range of issues that are not all wholly 
relevant to the Athlome Project. Nevertheless, certain key principles must be noted here that 
will inform the governance framework for Athlome: 1) the consortia are global in reach, but 
there is no universal agreement on the precise nature of ethically justifiable governance for 
biobanking; 2) given the globality of the consortia, no single regional (e.g., European, 
American) framework ought to be adopted; 3) a general framework drawing on widely shared 
principles should be discussed and adopted. Chief among the concerns, but only one among 
several, is the problem of consent. 
Each of the projects that comprise Athlome are existing bioguardians with a duty to protect 
the rights of participants who have contributed their samples to the individual projects noted 
above. The collection, storage, access to, and use by researchers of those samples have been 
approved by relevant regulatory authorities (e.g., institutional review boards, research ethics 
committees, national health services research ethics services) appropriate to the lead 
institution of the individual projects/consortia. Existing procedures do not currently extend to 
the sharing of samples beyond the study, since consent models are prospective (i.e., they 
guide future actions of researchers) and typically entail a form of specificity and the specific 
consent obtained varies between project partners. No retrospective consent is feasible, and 
this is a widely shared problem for biobank development. Since the form of collaboration 
Athlome envisages was not laid out before participants gave their consent, it might be 
concluded that the sharing of data beyond the original research group and its stated purposes 
invalidates that consent. The problem for Athlome is not an uncommon one for biobank 
collaborations since it seeks retrospective extension of the consent model. 
An ethical solution to this problem and related consent problems for new participants is to 
consider the use of a technique such as “broad consent.” The nomenclature here is important 
since this notion is variously described as “broad consent,” “blanket consent,” “future 
consent,” “hypothetical consent,” “passive/tacit/silent consent,” or “waived consent” (4, 5). 
This would entail asking participants to agree to future unspecified uses of their data that are 
un(der)determined in the consent process and relevant forms (6). Without sufficient grasp of 
the uses of the data or with whom it might be shared, this process fails the test of 
“comprehension”: a user must understand sufficiently what they are agreeing to (3). Another 
possibility going forward would be “meta-consent,” where consent is sought for broad 
categories of unspecified future research (7, 8). Others have argued with respect to 
biobanking that the ethical issues entailed (e.g., privacy, confidentiality, ownership of access 
to the data) may be sufficiently assuaged by rigorous anonymization (1) and associated 
practices of data storage, though this is far from universally agreed upon (2). 
The Athlome project will develop principles and protocols for safeguarding participants rights 
to access, confidentiality, privacy of data, and assurances that there is no significant mission 
drift of the kind of which is permitted under some conceptions of broad consent (or its 
similes). This would, for example, prohibit commercialization of participants' data. To 
preserve the integrity of this process and the principles, rigorous anonymization processes 
will be developed by a partner institution that does not have any direct role in data collection, 
storage, or analysis. This will assure independence and integrity to the process. This is 
especially important in this case since some of the research participants are public figures, 
which increases the likelihood that someone might be interested in reidentifying their data 
and genomic sequences. The independent institution would also have an oversight of each 
new proposal for the Athlome Project going forward to ensure compliance with those 
principles and protocols. 
In conclusion, by presenting the main study cohorts and projects that are currently included in 
the Athlome consortium not only do we intend to show a global view of the main studies and 
initiatives that will be performed in the foreseeable future in the field of sports genomics (and 
that are likely to provide new exciting findings), we also wish to motivate potential 
collaboration initiatives with other research groups worldwide. International collaborations 
are likely to go well beyond the study of sports performance per se. Indeed, the Athlome 
consortium presents a unique chance to study the biology of the best elite athletes across most 
ethnicities, which is profoundly interesting from a medical point of view. World-class athletes 
represent the actual end-point of the human continuum of fitness-related phenotypes. In this 
regard, there is growing evidence (coming from both human and rodent study approaches, 
such as those included in the consortium) that not only physical activity levels but also 
individual fitness levels (a trait that has a strong genetic component independent of activity 
levels) are inversely associated with the risk of major cardiometabolic diseases of Western 
civilization, several cancer types, and Alzheimer's disease. Thus, studying the genes of elite 
athletes offers a unique chance to gain insight into important medical conditions, including 
genetic predisposition (or resilience) to chronic disease. Indeed, the “rare-common” strategy, 
underpinned by ethically sound research governance, is a valuable approach model to 
examine general mechanisms of disease pathophysiology, with world-class athletes 
representing the “rare” (“super-fit”) human phenotype. Finally, identifying genetic markers of 
exercise capacity, adaptation to exercise programs, and the predisposition to injury is certain 
to provide useful information to prescribe personalized exercise interventions in the context 
of 21st-century medicine, which should not be based only on identifying new drug targets but 
also on implementing lifestyle interventions for disease prevention at the individual level. 
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The Athlome Project Consortium. Genomic, epigenomic, transcriptomic, proteomic, and 
metabolomic studies are being conducted by the participating centers to address questions in 
the 3 main research areas: elite performance, training response, and injury. Future 
investigations planned include studies on genetic modification. 
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